Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
KYGEVVI (DOXECITINE; DOXRIBTIMINE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
KYGEVVI
NDA
Get alerts
DOXECITINE; DOXRIBTIMINE | N219792 | UCB INC
1 strength
2 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
2 unique patents, 1 exclusivity by expiration date
Active (2)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
Today
10471087
Aug. 7, 2036
11649259
Aug. 19, 2040
NCE
Nov. 3, 2030
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 2GM/PACKET;2GM/PACKET
RLD
2 patents
1 exclusivity
▴
FOR SOLUTION;ORAL | Approved: Nov 3, 2025
Patents (2)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
10471087
Aug 7, 2036
—
—
—
U-4358
TREATMENT OF THYMIDINE KINASE 2 DEFICIENCY (TK2D) IN ADULTS AND PEDIATRIC PATIENTS WITH AN AGE OF SYMPTOM ONSET ON OR BEFORE 12 YEARS
—
11649259
Aug 19, 2040
—
—
Yes
U-4358
TREATMENT OF THYMIDINE KINASE 2 DEFICIENCY (TK2D) IN ADULTS AND PEDIATRIC PATIENTS WITH AN AGE OF SYMPTOM ONSET ON OR BEFORE 12 YEARS
—
Exclusivities (1)
Code
Date
Status
NCE
Nov 3, 2030
Active